Logo image of EBS

EMERGENT BIOSOLUTIONS INC (EBS) Stock Fundamental Analysis

NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD

4.92  -0.42 (-7.87%)

Premarket: 5.25 +0.33 (+6.71%)

Fundamental Rating

3

Overall EBS gets a fundamental rating of 3 out of 10. We evaluated EBS against 566 industry peers in the Biotechnology industry. EBS has a bad profitability rating. Also its financial health evaluation is rather negative. EBS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

EBS had negative earnings in the past year.
In the past year EBS had a positive cash flow from operations.
In multiple years EBS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: EBS reported negative operating cash flow in multiple years.
EBS Yearly Net Income VS EBIT VS OCF VS FCFEBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

EBS has a better Return On Assets (-13.72%) than 83.75% of its industry peers.
With a decent Return On Equity value of -39.48%, EBS is doing good in the industry, outperforming 71.02% of the companies in the same industry.
Industry RankSector Rank
ROA -13.72%
ROE -39.48%
ROIC N/A
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
EBS Yearly ROA, ROE, ROICEBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of EBS (34.72%) is better than 73.67% of its industry peers.
EBS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EBS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
EBS Yearly Profit, Operating, Gross MarginsEBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

EBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EBS has been increased compared to 1 year ago.
Compared to 5 years ago, EBS has more shares outstanding
Compared to 1 year ago, EBS has a worse debt to assets ratio.
EBS Yearly Shares OutstandingEBS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
EBS Yearly Total Debt VS Total AssetsEBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.90, we must say that EBS is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.90, EBS is doing good in the industry, outperforming 67.31% of the companies in the same industry.
The Debt to FCF ratio of EBS is 18.54, which is on the high side as it means it would take EBS, 18.54 years of fcf income to pay off all of its debts.
EBS has a better Debt to FCF ratio (18.54) than 92.76% of its industry peers.
EBS has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
EBS's Debt to Equity ratio of 1.37 is on the low side compared to the rest of the industry. EBS is outperformed by 80.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF 18.54
Altman-Z 0.9
ROIC/WACCN/A
WACC9.01%
EBS Yearly LT Debt VS Equity VS FCFEBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 3.69 indicates that EBS has no problem at all paying its short term obligations.
EBS has a Current ratio of 3.69. This is comparable to the rest of the industry: EBS outperforms 44.17% of its industry peers.
A Quick Ratio of 1.77 indicates that EBS should not have too much problems paying its short term obligations.
The Quick ratio of EBS (1.77) is worse than 77.56% of its industry peers.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 1.77
EBS Yearly Current Assets VS Current LiabilitesEBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.34% over the past year.
The Revenue for EBS has decreased by -14.06% in the past year. This is quite bad
EBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.15% yearly.
EPS 1Y (TTM)94.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.49%
Revenue 1Y (TTM)-14.06%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-29.61%

3.2 Future

EBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.93% yearly.
The Revenue is expected to grow by 7.53% on average over the next years.
EPS Next Y344.35%
EPS Next 2Y163.67%
EPS Next 3Y23.19%
EPS Next 5Y16.93%
Revenue Next Year-25.27%
Revenue Next 2Y-5.35%
Revenue Next 3Y-11.94%
Revenue Next 5Y7.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EBS Yearly Revenue VS EstimatesEBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EBS Yearly EPS VS EstimatesEBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

EBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 6.50, which indicates a rather cheap valuation of EBS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EBS indicates a rather cheap valuation: EBS is cheaper than 98.59% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.49. EBS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 6.5
EBS Price Earnings VS Forward Price EarningsEBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EBS is valued cheaply inside the industry as 94.35% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, EBS is valued cheaper than 98.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.47
EV/EBITDA 30.46
EBS Per share dataEBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

EBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EBS's earnings are expected to grow with 23.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y163.67%
EPS Next 3Y23.19%

More info and screens

0

5. Dividend

5.1 Amount

EBS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (5/1/2025, 8:56:59 PM)

Premarket: 5.25 +0.33 (+6.71%)

4.92

-0.42 (-7.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/amc
Earnings (Next)05-07 2025-05-07
Inst Owners64.96%
Inst Owner Change-0.95%
Ins Owners1.08%
Ins Owner Change15.13%
Market Cap267.35M
Analysts74.29
Price Target13.77 (179.88%)
Short Float %17.01%
Short Ratio6.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)489.44%
Min EPS beat(2)110%
Max EPS beat(2)868.88%
EPS beat(4)3
Avg EPS beat(4)250.93%
Min EPS beat(4)-143.07%
Max EPS beat(4)868.88%
EPS beat(8)3
Avg EPS beat(8)40.12%
EPS beat(12)4
Avg EPS beat(12)-225.01%
EPS beat(16)6
Avg EPS beat(16)-178.43%
Revenue beat(2)0
Avg Revenue beat(2)-13.26%
Min Revenue beat(2)-24.3%
Max Revenue beat(2)-2.22%
Revenue beat(4)2
Avg Revenue beat(4)10.31%
Min Revenue beat(4)-24.3%
Max Revenue beat(4)35.04%
Revenue beat(8)5
Avg Revenue beat(8)14.52%
Revenue beat(12)7
Avg Revenue beat(12)9.27%
Revenue beat(16)8
Avg Revenue beat(16)4.69%
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-74.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-27.04%
Revenue NY rev (3m)-27.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.5
P/S 0.26
P/FCF 7.47
P/OCF 4.55
P/B 0.55
P/tB N/A
EV/EBITDA 30.46
EPS(TTM)-0.31
EYN/A
EPS(NY)0.76
Fwd EY15.4%
FCF(TTM)0.66
FCFY13.39%
OCF(TTM)1.08
OCFY21.96%
SpS19.21
BVpS8.88
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.72%
ROE -39.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.72%
FCFM 3.43%
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF 18.54
Debt/EBITDA 24.31
Cap/Depr 21.05%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion 215.02%
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 1.77
Altman-Z 0.9
F-Score6
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)106.07%
Cap/Depr(5y)126.37%
Cap/Sales(3y)13.29%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.49%
EPS Next Y344.35%
EPS Next 2Y163.67%
EPS Next 3Y23.19%
EPS Next 5Y16.93%
Revenue 1Y (TTM)-14.06%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-29.61%
Revenue Next Year-25.27%
Revenue Next 2Y-5.35%
Revenue Next 3Y-11.94%
Revenue Next 5Y7.53%
EBIT growth 1Y76.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year326.21%
EBIT Next 3Y55.51%
EBIT Next 5Y39.09%
FCF growth 1Y113.55%
FCF growth 3Y-28.05%
FCF growth 5Y-17.04%
OCF growth 1Y128.45%
OCF growth 3Y-43.25%
OCF growth 5Y-20.77%